Treatment Tips as COVID-19 Complicates CVD Management in Diabetes
COVID-19 and related cardio-renal-pulmonary damage can profoundly affect the cardiovascular risk management of people with diabetes. It is recommended to continue ACE inhibitors and angiotensin receptor blockers, both SGLT2 inhibitors and GLP-1 receptor agonists have anti-inflammatory activities, which might be beneficial for patients with COVID-19. However, several expert groups in diabetes have previously advised that […]
Cardiovascular disease and COVID-19
Respiratory illness is the dominant clinical manifestation of COVID-19; CVD involvement occurs rarely. Acute cardiac injury, defined as a significant elevation of cardiac troponins, is the most commonly reported cardiac abnormality in COVID-19 affecting ~8–12% of patients. A Chinese study reported the incidence of heart failure in 52% of COVID-19 patients who subsequently died and […]